ProShare Advisors
NMRA icon

ProShare Advisors’s Neumora Therapeutics NMRA Stock Holding History

ProShare Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.2K Buy
+19,508
New +$37.1K ﹤0.01% 1877
2025
Q2 		– Sell
-25,738
Closed -$25.7K – 2148
2025
Q1 		$25.7K Sell
25,738
-5,604
-18% -$9.6K ﹤0.01% 2020
2024
Q4 		$332K Sell
31,342
-448
-1% -$5.37K ﹤0.01% 1552
2024
Q3 		$420K Buy
+31,790
New +$371K ﹤0.01% 1248

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ProShare Advisors's NMRA Position: Q2 2026 in Review

ProShare Advisors opened a new position in Neumora Therapeutics (NMRA) in Q2 2026: 19,508 shares worth $33.2K. The stake represents ﹤0.01% of the portfolio and ranks #1877 among its holdings. This is a return to the name: ProShare Advisors previously reported a position in NMRA as recently as Q1 2025.

ProShare Advisors first reported a position in NMRA in Q3 2024 and has held it in 4 quarters since. The position peaked at $420K in Q3 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • ProShare Advisors held 19,508 shares of Neumora Therapeutics worth $33.2K as of Q2 2026.
  • Neumora Therapeutics was a new ProShare Advisors position in Q2 2026.
  • Neumora Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1877 holding.
  • ProShare Advisors first reported a position in Neumora Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • ProShare Advisors's Neumora Therapeutics position peaked at $420K in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.